Egetis Therapeutics AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 57.6 million compared to SEK 22.6 million a year ago. Revenue was SEK 57.6 million compared to SEK 22.6 million a year ago.

Net loss was SEK 326.9 million compared to SEK 193.8 million a year ago. Basic loss per share from continuing operations was SEK 1.3 compared to SEK 1 a year ago. Diluted loss per share from continuing operations was SEK 1.3 compared to SEK 1 a year ago.